Literature DB >> 25441110

Progress in acute myeloid leukemia.

Tapan M Kadia1, Farhad Ravandi2, Susan O'Brien2, Jorge Cortes2, Hagop M Kantarjian2.   

Abstract

Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AML; Review; Targeted therapy

Mesh：

Substances：

Year:  2014        PMID： 25441110      PMCID： PMC4344862          DOI： 10.1016/j.clml.2014.08.006

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


  120 in total

1.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

2.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Authors:  Katharina Wagner; Frederik Damm; Gudrun Göhring; Kerstin Görlich; Michael Heuser; Irina Schäfer; Oliver Ottmann; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna A Raghavachar; Walter Fiedler; Hartmut H Kirchner; Wolfram Brugger; Manuela Zucknick; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Jürgen Krauter
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

4.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

5.  The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.

Authors:  Claire L Green; Catherine M Evans; Robert K Hills; Alan K Burnett; David C Linch; Rosemary E Gale
Journal:  Blood       Date:  2010-07-22       Impact factor: 22.113

6.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Kati Maharry; Yue-Zhong Wu; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Susan P Whitman; Heiko Becker; Sebastian Schwind; Klaus H Metzeler; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 50.717

7.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

8.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

9.  Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Authors:  Felicitas Thol; Frederik Damm; Katharina Wagner; Gudrun Göhring; Brigitte Schlegelberger; Dieter Hoelzer; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna Raghavachar; Walter Fiedler; Hartmut Kirchner; Gerhard Heil; Michael Heuser; Jürgen Krauter; Arnold Ganser
Journal:  Blood       Date:  2010-04-26       Impact factor: 25.476

10.  Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Authors:  Nicolas Boissel; Olivier Nibourel; Aline Renneville; Claude Gardin; Oumedaly Reman; Nathalie Contentin; Dominique Bordessoule; Cécile Pautas; Thierry de Revel; Bruno Quesnel; Pascal Huchette; Nathalie Philippe; Sandrine Geffroy; Christine Terre; Xavier Thomas; Sylvie Castaigne; Hervé Dombret; Claude Preudhomme
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 50.717
View more
  18 in total

Review 1.  Frontline treatment of acute myeloid leukemia in adults.

Authors:  Gevorg Tamamyan; Tapan Kadia; Farhad Ravandi; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Naval Daver; Maro Ohanian; Hagop Kantarjian; Marina Konopleva
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-11       Impact factor: 6.312

2.  A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.

Authors:  Silvia Grassilli; Ervin Nika; Elisabetta Lambertini; Federica Brugnoli; Roberta Piva; Silvano Capitani; Valeria Bertagnolo
Journal:  Cell Oncol (Dordr)       Date:  2016-08-01       Impact factor: 6.730

3.  Prognostic significance of osteopontin in acute myeloid leukemia: A meta-analysis.

Authors:  Yong-Bing Chen; Si-Mei Ren; Si-Dan Li; Zhongli Du
Journal:  Mol Clin Oncol       Date:  2017-06-28

4.  Translesion synthesis DNA polymerases η, ι, and ν promote mutagenic replication through the anticancer nucleoside cytarabine.

Authors:  Jung-Hoon Yoon; Jayati Roy Choudhury; Louise Prakash; Satya Prakash
Journal:  J Biol Chem       Date:  2019-11-04       Impact factor: 5.157

5.  A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Authors:  Keith W Pratz; Michelle A Rudek; Ivana Gojo; Mark R Litzow; Michael A McDevitt; Jiuping Ji; Larry M Karnitz; James G Herman; Robert J Kinders; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Douglas E Gladstone; Mark J Levis; Hua-Ling Tsai; Gary Rosner; Alice Chen; Scott H Kaufmann; Judith E Karp
Journal:  Clin Cancer Res       Date:  2016-08-22       Impact factor: 12.531

6.  Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.

Authors:  Keina M C Dourado; June Baik; Vanessa K P Oliveira; Miriam Beltrame; Ami Yamamoto; Charles P Theuer; Camila A V Figueiredo; Michael R Verneris; Rita C R Perlingeiro
Journal:  Blood       Date:  2017-03-28       Impact factor: 22.113

7.  The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia.

Authors:  Jessica R Galloway-Peña; Daniel P Smith; Pranoti Sahasrabhojane; Nadim J Ajami; W Duncan Wadsworth; Naval G Daver; Roy F Chemaly; Lisa Marsh; Shashank S Ghantoji; Naveen Pemmaraju; Guillermo Garcia-Manero; Katayoun Rezvani; Amin M Alousi; Jennifer A Wargo; Elizabeth J Shpall; Phillip A Futreal; Michele Guindani; Joseph F Petrosino; Dimitrios P Kontoyiannis; Samuel A Shelburne
Journal:  Cancer       Date:  2016-05-03       Impact factor: 6.860

8.  A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.

Authors:  Fan Xia; Sheng Ma; Yicong Bian; Di Yu; WenXia Ma; Miao Miao; Chenrong Huang; Liyan Miao
Journal:  Cancer Chemother Pharmacol       Date:  2019-10-25       Impact factor: 3.333

Review 9.  Acute myeloid leukemia: current progress and future directions.

Authors:  Hagop Kantarjian; Tapan Kadia; Courtney DiNardo; Naval Daver; Gautam Borthakur; Elias Jabbour; Guillermo Garcia-Manero; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2021-02-22       Impact factor: 11.037

Review 10.  RNA modifications in hematopoietic malignancies: a new research frontier.

Authors:  Ying Qing; Rui Su; Jianjun Chen
Journal:  Blood       Date:  2021-08-26       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.